Johnson & Johnson (NYSE:JNJ) Stock Rating Reaffirmed as Buy by Guggenheim

Johnson & Johnson (NYSE:JNJ)‘s stock had its “buy” rating reaffirmed by investment analysts at Guggenheim in a note issued to investors on Wednesday, Marketbeat.com reports. They currently have a $287.00 price target on the stock. Guggenheim’s price target would suggest a potential upside of 10.29% from the stock’s previous close.

Several other equities research analysts also recently weighed in on the stock. HSBC upped their target price on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Bank of America reaffirmed a “neutral” rating and set a $278.00 target price on shares of Johnson & Johnson in a research note on Tuesday, September 29th. JPMorgan Chase & Co. upped their target price on shares of Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 29th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $282.00 target price on shares of Johnson & Johnson in a research note on Thursday, July 16th. Finally, Raymond James Financial set a $280.00 target price on shares of Johnson & Johnson in a research note on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $276.22.

Johnson & Johnson Stock Up 2.1%

JNJ traded up $5.45 during trading hours on Wednesday, hitting $260.23. 1,247,195 shares of the company’s stock were exchanged, compared to its average volume of 7,959,004. Johnson & Johnson has a 12-month low of $184.66 and a 12-month high of $281.07. The firm has a 50 day moving average of $265.86 and a 200 day moving average of $248.63. The firm has a market cap of $627.13 billion, a P/E ratio of 30.14, a price-to-earnings-growth ratio of 2.48 and a beta of 0.21. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. During the same period in the prior year, the firm earned $2.77 EPS. The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Analysts predict that Johnson & Johnson will post 11.54 EPS for the current fiscal year.

Insider Activity

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the sale, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 87,569 shares of company stock valued at $23,064,544. 0.16% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of JNJ. Outlook Capital Management LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter valued at $28,000. Matrix Trust Co grew its position in shares of Johnson & Johnson by 56.3% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after buying an additional 54 shares during the last quarter. Hyposwiss Advisors SA purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at $42,000. Montgomery Financial Services LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter valued at $43,000. Finally, Polaris Financial Partners purchased a new position in shares of Johnson & Johnson in the 3rd quarter valued at $56,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst support: Guggenheim reaffirmed its “Buy” rating and set a $287 price target, implying roughly 10% upside from recent levels. RBC Capital also maintained its “Buy” rating. RBC Capital Keeps Their Buy Rating on Johnson & Johnson
• Positive Sentiment: Oncology pipeline progress: J&J reported that its Tecvayli-Talvey combination reduced the relative risk of disease progression or death by 89% and the risk of death by 62% in relapsed or refractory multiple myeloma. The results could support broader or earlier use of the combination, although it remains an investigational treatment. 2026 Cancer Treatment Advances
• Positive Sentiment: ICOTYDE durability: Two-year Phase 3 data showed that J&J’s oral psoriasis treatment maintained skin clearance and consistent safety through Week 112, strengthening its potential as a targeted alternative for difficult-to-treat areas. ICOTYDE Long-Term Psoriasis Data
• Positive Sentiment: Dividend appeal: J&J has recorded 64 consecutive years of dividend increases, reinforcing its reputation as a defensive income stock and potentially attracting investors amid market volatility. Johnson & Johnson Dividend Royalty Status
• Neutral Sentiment: Upcoming earnings: Investors are assessing whether Innovative Medicines growth can offset a recent MedTech slowdown, while the company’s next quarterly report approaches. Vision, Orthopedics and Surgery could support a second-half recovery, but competitive pressure remains.
• Negative Sentiment: Longer-term risks: Analysts and commentators continue to flag biosimilar competition, a roughly $4 billion 2027 patent cliff, MedTech headwinds and unresolved talc litigation. These issues could constrain growth and valuation even with strong dividend reliability.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.